Expertise in
7
conditions

Nizar J. Bahlis

Calgary, AB, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Calgary, AB, CA 

Overview

Nizar Bahlis practices practicing medicine in Calgary, Canada.

Mr. Bahlis is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Mycobacterium Avium Complex Infections, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 201 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Calgary, AB, Canada
Other Locations
Calgary, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 04, 2023
Intervention Type: Biological
Study Drugs: DCdP, DCd+P
Study Phase: Phase 2
Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
Enrollment Status: Completed
Publish Date: September 25, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

201 Total Publications

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Journal: The New England journal of medicine
Published: May 29, 2026

Frequently Asked Questions about Nizar J. Bahlis

Is Nizar J. Bahlis a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Nizar J. Bahlis is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nizar J. Bahlis participate in research or clinical trials?

Yes. Nizar J. Bahlis has published 201 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Nizar J. Bahlis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bahlis's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile